{"Clinical Trial ID": "NCT00193063", "Intervention": ["INTERVENTION 1:", "- Gemcitabine/Trastuzumab", "All patients enrolled in this trial were treated with a combination of gemcitabine and trastuzumab. Gemcitabine 1000 mg/m2 was administered intravenously on days 1, 8 and 15 of a 28-day cycle. Trastuzumab was administered as an intravenous charge dose of 4 mg/kg on day 1 and thereafter at a dose of 2 mg/kg per week."], "Eligibility": ["Incorporation criteria:", "To be included in this study, you must meet the following criteria:", "Her-2 positive metastatic breast cancer confirmed by biopsy", "A Measurable Disease", "\u2022 Capable of carrying out activities of daily life without", "No previous chemotherapy with gemcitabine", "No more than one prior chemotherapy regimen for metastatic breast cancer", "\u2022 Sensitivity of bone marrow, liver and kidney function", "Normal heart function", "\u2022 Provide written informed consent before entering this study.", "- Exclusion criteria:", "You may not participate in this study if any of the following applies to you:", "Received prior treatment with gemcitabine", "History of brain metastases", "Underlying serious disorders", "Note: There are other inclusion and exclusion criteria. The study centre will determine if you meet all the criteria. If you are not eligible for the trial, the study staff will explain the reasons. If you are eligible, the study staff will explain the trial in detail and answer any questions you may have."], "Results": ["Performance measures:", "Overall response rate (OR)", "By Response Solid Tumour Assessment Criteria (RCIST v1.0) for target lesions and evaluated by MRI or CT: complete response (RC), elimination of all target lesions; partial response (PR), >=30% decrease in the sum of the longest diameter of target lesions; overall response (RO) = CR + PR.", "Time limit: 18 months", "Results 1:", "Title of arm/group: Gemcitabine/Trastuzumab", "All patients entering this trial were treated with a combination of gemcitabine and trastuzumab. Gemcitabine 1000 mg/m2 was administered intravenously on days 1, 8 and 15 of a 28-day cycle. Trastuzumab was administered as an intravenous charge dose of 4 mg/kg on day 1 and thereafter at a dose of 2 mg/kg per week.", "Total number of participants analysed: 37", "Type of measurement: Number", "Unit of measure: percentage of participants 30 (17 to 46)"], "Adverse Events": ["Undesirable Events 1:", "Total: 14/41 (34.15 per cent)", "Ischemia heart/infarction 2/41 (4.88 %)", "Dual Ulcer 1/41 (2.44%)", "Vomiting 2/41 (4.88 per cent)", "Fever 2/41 (4.88 per cent)", "Death NOS 1/41 (2.44 %)", "Hepatic impairment 1/41 (2.44%)", "Infection - pneumonia 2/41 (4.88 per cent)", "Infection - port site 2/41 (4.88%)", "urinary tract infection 1/41 (2.44%)", "\u2022 Disease progression 3/41 (7.32%)", "Confusion 1/41 (2.44 per cent)"]}